|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1992-1-17
|
|
pubmed:abstractText |
Six patients with rheumatoid arthritis were treated with a CD7 mouse monoclonal antibody, RFT2, daily for 15 days. Only two patients had a significant improvement in clinical disease activity which lasted 7-14 days. No serious adverse effects occurred although all patients developed antibodies against mouse immunoglobulin. During treatment T-lymphocyte numbers decreased and T-lymphocyte CD7 expression was absent in all but one patient.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0263-7103
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
459-63
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1720991-Adult,
pubmed-meshheading:1720991-Antibodies, Monoclonal,
pubmed-meshheading:1720991-Antigens, CD,
pubmed-meshheading:1720991-Antigens, CD7,
pubmed-meshheading:1720991-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:1720991-Arthritis, Rheumatoid,
pubmed-meshheading:1720991-Female,
pubmed-meshheading:1720991-Humans,
pubmed-meshheading:1720991-Immunosuppression,
pubmed-meshheading:1720991-Male,
pubmed-meshheading:1720991-Middle Aged,
pubmed-meshheading:1720991-Synovial Membrane,
pubmed-meshheading:1720991-T-Lymphocyte Subsets
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody.
|
|
pubmed:affiliation |
Rheumatology Unit, United Medical School, Guy's Hospital, London, England.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
